| Dr Jonathan W Mellema, MD | |
|
1801 19th Ave Sw, Willmar, MN 56201-4946 | |
| (320) 231-3277 | |
| (320) 214-5758 |
| Full Name | Dr Jonathan W Mellema |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 24 Years |
| Location | 1801 19th Ave Sw, Willmar, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083680458 | NPI | - | NPPES |
| 312128300 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 47540 (Minnesota) | Secondary |
| 207Y00000X | Otolaryngology | 11483 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Marshall Regional Medical Ctr | Marshall, MN | Hospital |
| Carris Health Llc | Willmar, MN | Hospital |
| Madison Hospital | Madison, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Appleton Area Health | 7618952565 | 16 |
| Janning Ent Center, Llc | 5496788077 | 3 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Lac Qui Parle Clinic Of Madison, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144266156 PECOS PAC ID: 5799727707 Enrollment ID: O20050531000484 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Janning Ent Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952332629 PECOS PAC ID: 5496788077 Enrollment ID: O20050914000650 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Family Surgery Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1831200120 PECOS PAC ID: 8022043785 Enrollment ID: O20050930000467 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Appleton Area Health |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1578590626 PECOS PAC ID: 7618952565 Enrollment ID: O20060504000767 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Appleton Area Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730126673 PECOS PAC ID: 7618952565 Enrollment ID: O20060818000114 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Appleton Area Health |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1649333923 PECOS PAC ID: 7618952565 Enrollment ID: O20080208000444 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Entity Name | Appleton Area Health |
|---|---|
| Entity Type | Part A Provider - Rural Health Clinic |
| Entity Identifiers | NPI Number: 1730126673 PECOS PAC ID: 7618952565 Enrollment ID: O20121217000417 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan W Mellema, MD 1801 19th Ave Sw, Willmar, MN 56201-4946 Ph: (320) 231-3277 | Dr Jonathan W Mellema, MD 1801 19th Ave Sw, Willmar, MN 56201-4946 Ph: (320) 231-3277 |
News Archive
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.
The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 4 days ago
Dr. Martin Heinz Janning, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1801 19th Ave Sw, Willmar, MN 56201 Phone: 320-231-3277 Fax: 320-214-5758 | |
Dr. Jennifer A Pesola, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-231-5000 Fax: 320-231-5067 |